D Amp M Pharma Peru Sac May 2026

Any pharmaceutical entity operating in Peru must adhere to the strict oversight of the Dirección General de Medicamentos, Insumos y Drogas (DIGEMID) – the country’s equivalent of the FDA. D amp M Pharma Peru SAC’s operational legitimacy hinges on maintaining current Good Distribution Practices (GDP) and Good Storage Practices (GSP) certifications.

According to publicly available DIGEMID registries, D amp M Pharma Peru SAC holds authorization for the following activities:

The company’s compliance record is a key differentiator in an industry where counterfeit or mishandled drugs remain a concern in certain Latin American markets. By maintaining ISO and local health authority standards, D amp M Pharma Peru SAC assures partners of product integrity from port of entry to point of dispensation.

The Peruvian pharmaceutical market is projected to grow at a CAGR of 5–7% through 2030, driven by an aging population, rising chronic disease prevalence, and expanded healthcare coverage under Universal Health Insurance (SIS). For D amp M Pharma Peru SAC, several growth avenues exist:

If the company successfully secures more DIGEMID authorizations for advanced therapies (e.g., gene therapy vectors or monoclonal antibodies), it could ascend from a mid-tier wholesaler to a specialty logistics leader.

D amp M Pharma Peru SAC is officially registered as a "Sociedad Anónima Cerrada" (SAC) – a closed corporation under Peruvian law. This legal designation indicates a private entity with a limited number of shareholders, often family-owned or operated by a small group of investors. The "SAC" suffix is common among mid-sized Peruvian firms that prioritize agility and direct control over public trading.

The "D amp M" in the name typically denotes the founding partners or core principles (e.g., "Development and Marketing" or the initials of the founders), though public records suggest a focus on pharmaceutical distribution and specialized medical supplies. Unlike generic drugstore chains, D amp M Pharma Peru SAC positions itself as a B2B wholesaler and institutional supplier, working directly with clinics, pharmacies, and government health programs.

As Peru continues to strengthen its healthcare infrastructure, D & M Pharma Peru SAC remains at the forefront, embracing innovation, digital transformation, and continuous training. The goal is not just to grow as a business, but to contribute actively to the well-being of every Peruvian citizen. d amp m pharma peru sac

D & M Pharma Peru SAC
Trust. Quality. Commitment to health.

(Insert contact details, RUC number, and physical address as applicable)

D&M Pharma Peru S.A.C. (also known as D&M Pharma or DYM) is a pharmaceutical company based in Lima, Peru, that specializes in the commercialization and marketing of health products. Established in 2007, the company is a strategic partner of Argentina’s Laboratorio Cassará and focuses on providing accessible, high-quality respiratory and general health solutions.

The following guide outlines the company's core operations, regulatory environment, and contact channels. 1. Company Profile & Mission

Core Focus: D&M Pharma operates in the wholesale of non-durable goods, specifically pharmaceutical products.

Partnership: It serves as the local representative and strategic ally for the renowned Laboratorio Cassará from Argentina, distributing their product lines in the Peruvian market.

Mission: Their stated objective is to support the medical community and provide patients with safe, effective, and ethical treatments, particularly for respiratory health. 2. Operational & Regulatory Standards Any pharmaceutical entity operating in Peru must adhere

To maintain its position in the pharmaceutical industry, D&M Pharma Peru adheres to strict local and international standards:

Regulatory Compliance: The company follows the BPA (Buenas Prácticas de Almacenamiento)—Good Storage Practices—as mandated by Peruvian health authorities.

Quality Assurance: Their technical leadership actively participates in national industry bodies, such as the Lima Chamber of Commerce (COMSALUD), ensuring alignment with modern health regulations.

Pharmacovigilance: D&M maintains a dedicated system for monitoring the safety and efficacy of its products once they are on the market. 3. Key Product Segments

While specific catalogs are often reserved for medical professionals, their presence typically spans:

Respiratory Health: Specialized treatments for asthma and other pulmonary conditions (linked to the Cassará expertise).

Miscellaneous Pharmaceuticals: A variety of ethical and over-the-counter (OTC) products intended for general healthcare. 4. Contact & Support Information The company’s compliance record is a key differentiator

For medical inquiries, pharmacovigilance reports, or commercial inquiries, you can reach the company through their official website:

Main Office: Av. Pablo Carriquiry 660, Piso 3, San Borja, Lima, Peru. General Phone: +51 1 2216662.

Pharmacovigilance Email: farmacovigilancia@dympharmaperu.com.

Social Channels: Professional updates and corporate news are frequently posted on the D&M Pharma Perú LinkedIn page. D & M Pharma Peru S.A.C. Company Profile - EMIS

Beyond chemical drugs, "Pharma" entities often distribute medical devices, surgical sutures, and diagnostic reagents. If D & M Pharma deals in cold-chain products (vaccines or insulin), they must maintain strict temperature-controlled warehouses.

In the rapidly evolving landscape of the Peruvian pharmaceutical industry, few names have garnered as much attention among healthcare professionals and distributors as D amp M Pharma Peru SAC. As a specialized entity operating within one of South America’s most dynamic healthcare markets, this company represents a critical link in the supply chain of medicines, medical devices, and pharmaceutical services.

Understanding the operations, compliance standards, and market influence of D amp M Pharma Peru SAC is essential for stakeholders ranging from hospital procurement managers to international drug manufacturers looking to enter the Andean region. This article provides an exhaustive analysis of the company’s structure, regulatory standing, product portfolio, and strategic importance in Peru.